Analystreport

CELLECT BIOTECH/S (NASDAQ: APOP) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.

Cellect Biotechnology Ltd. - American Depositary Shares  (APOP) 
US:NASDAQ Investor Relations: cellect.co